DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Georgia Universities Join NIH-funded National Study of Bone Marrow Transplant for SCD
The Medical College of Georgia (MCG) and Augusta University Health (AU Health) have joined the first large, national clinical trial investigating bone marrow transplantation as part of the standard of care (SoC) for patients with sickle cell disease (SCD).
The National Institutes of Health (NIH)-funded study will conduct bone marrow transplants in patients who have high-risk SCD and who have a compatible bone marrow donor (typically a sibling, but it also can be an unrelated donor), and follow patients for whom a compatible donor wasn’t found, while giving them SoC treatment.
+myBinderRelated Content
-
news & eventsMaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell DiseaseMaxCyte, a US-based global company dedic...
-
education & researchQ & A Facts on Hydroxyurea for Children With Sickle Cell DiseaseIt is time to rethink hydroxyurea for th...
-
news & eventsToronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
-
education & researchEarly occurrence of red blood cell alloimmunization in patients with sickle cell diseaseRed blood cell (RBC) alloimmunization is...
-
news & eventsPediatric sickle cell study stopped early due to positive resultsA national sickle cell disease study inv...
-
news & eventsEmmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
news & eventsEmmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)AmerisourceBergen, a global healthcare s...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.